NCT02259621View on ClinicalTrials.gov

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 14, 2022

Study Completion Date

October 31, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Nivolumab

Anti-PD-1 Therapy

DRUG

Carboplatin

Anti-PD-1 Therapy

DRUG

Paclitaxel

Anti-PD-1 Therapy

DRUG

Ipilimumab

Anti-PD-1 Therapy

Trial Locations (5)

10065

Memorial Sloan Kettering, New York

21224

Johns Hopkins at Bayview Medical Center, Baltimore

21287

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

98026

Swedish Cancer Insitute, Edmonds

H4 3J1

Johnathan Spicer, Montreal

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER